Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design.
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab075
Abstract: OBJECTIVES Clinical trials in early diffuse cutaneous systemic sclerosis (SSc) using the modified Rodnan skin score (mRSS) as the primary outcome measure have most often been negative. We wanted to assess how the definition of… read more here.
Keywords: manifestation; trial; disease; early diffuse ... See more keywords
A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1093/rheumatology/keac501
Abstract: OBJECTIVE Clinical trials in early diffuse systemic sclerosis (SSc) have consistently shown a placebo group response with a declining modified Rodnan skin score (mRSS), with negative outcomes. Our objective was to identify strategies using clinical… read more here.
Keywords: friction rubs; rna polymerase; enrichment; tendon friction ... See more keywords
A Phase II randomised controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS).
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1136/annrheumdis-2022-eular.694
Abstract: OBJECTIVES Although the painful and disabling features of early diffuse cutaneous systemic sclerosis (dcSSc) have an inflammatory basis and could respond to corticosteroids, corticosteroids are a risk factor for scleroderma renal crisis. Whether or not… read more here.
Keywords: prednisolone; systemic sclerosis; trial; diffuse cutaneous ... See more keywords